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COMMENTARY
BJD
British Journal of Dermatology
Skin cancer burden in lung transplant
recipients: we need to do better!
DOI: 10.1111/bjd.18903
Linked Article: Way et al. Br J Dermatol 2020; DOI: 10.1111/
bjd.18812
Solid organ transplant recipients (SOTRs) are at significantly
increased risk for multiple skin cancers.1 Skin cancer multiplic-
ity matters: immunosuppressed patients with multiple squa-
mous cell carcinomas (SCCs) have poorer outcomes.2 Routine
skin cancer surveillance and preventative strategies have been
widely adopted in many centres, but current practice may fall
short for lung transplant recipients (LTRs).
In this issue of the BJD, Way and colleagues3 quantify the
burden of new skin cancers developing annually in LTRs, and
the numbers are staggering. This study comes from Queens-
land, Australia, arguably the ‘skin cancer capital’ of the world,
but also a region with sophisticated strategies to combat skin
cancer in the general population, and with high levels of edu-
cation among patients and general practitioners.
High incidence rates for keratinocyte cancers (KCs) in
SOTRs have been extensively reported, usually based on first
primary KC. Here the authors assess total burden of KCs in a
prospective, population-based study. Eligibility was restricted
to patients stably transplanted for at least 1 year in whom
systemic retinoids or topical therapies had not been initiated
in the previous 6 months and 125 LTRs in Queensland com-
pleted the study. By choosing a population-based study and
by systematically cross-checking both public and private
pathology databases for confirmation of interval skin cancers,
these authors established age-standardized incidence rates of
447 per 1000 patient-years for SCC and 281 per 1000 per-
son-years for basal cell carcinoma (BCC). This is more than
double the age-standardized incidence rates for LTR SCC when
based on first primary SCC alone (201 per 1000 person-years)
and is 77 times higher than the estimated SCC incidence rate
in the general Queensland population.
Why do LTRs have such a high skin cancer risk? As in car-
diac transplantation, LTRs need greater levels of immunosup-
pression than renal or liver transplant recipients. This intense
immunosuppression interacts with previous and ongoing solar
ultraviolet (UV) exposure, creating a perfect storm for skin
carcinogenesis. LTRs have historically received azathioprine as
part of their maintenance immunosuppressive regimen,
although mycophenolate mofetil is now preferentially used.
Many LTRs also receive voriconazole for treatment or preven-
tion of fungal lung infections. Like azathioprine,4,5 voricona-
zole is photosensitizing to UVA6 and contributes to
carcinogenesis both directly and indirectly through mecha-
nisms that include generation of reactive oxygen species.
When examining risk factors associated with skin cancer
multiplicity, Way and colleagues found that ever use of
voriconazole increased risk of SCC (not BCC) twofold, and
treatment with voriconazole for 4 or more months increased
SCC risk 45-fold. Thus, regimens that include prophylactic
voriconazole will compound the already very high risk for
cutaneous SCC in LTRs.
As dermatologists, we are ideally placed to provide dedi-
cated OTR skin clinics for long-term skin surveillance, rapid
access for urgent problems and skin cancer risk reduction
management. Such opportunities are often limited during
transplant clinic consultations, in which many other clinical
problems compete for the transplant team’s time and
resources. Nonetheless, we should be aiming to develop skin
cancer prevention programmes for routine delivery within
transplantation clinics. Simple protocols, ideally using multi-
modal methods, could be created to support best practice in
sun protection and skin cancer education. Such approaches are
a focus of recent research efforts and may be a starting point
for addressing the huge and growing burden of OTR skin can-
cer so dramatically highlighted in this study.
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